Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Fumoleau

Showing results (81-90 of 152) with videos related to

Pageof 16
Sort By:
British Journal of Cancer|January 8, 2004
G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosisP Jézéquel, L Campion, M-P Joalland, et al.
Cancer|November 1, 1990
Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastasesC Jacquillat, D Khayat, P Banzet, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanomaC Jacquillat, D Khayat, P Banzet, et al.
European Journal of Cancer (Oxford, England : 1990)|December 26, 2001
Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancerF Caponigro, C Dittrich, J B Sorensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancerJ M Nabholtz, K Gelmon, M Bontenbal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1993
Usefulness of imaging ovarian cancer recurrence with In-111-labeled monoclonal antibody (OC 125) specific for CA 125 antigen. The INSERM Research Network (Nantes, Rennes, Reims, Vuillejuif, SaclayP Peltier, J P Dutin, J F Chatal, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2004
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group studyF Duffaud, M Borner, P Chollet, et al.
Cancer Research|June 1, 1989
Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomasJ F Chatal, J C Saccavini, J F Gestin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
Trastuzumab duration effects within patient prognostic subgroups in the PHARE trialA Kramar, T Bachelot, N Madrange, et al.
Pathologie-Biologie|November 1, 1992
[Intraperitoneal recombinant gamma interferon (RU 42369) efficacy in ovarian carcinomas. European BRM Study Group]J P Guastalla, E Pujade-Lauraine, N Colombo, et al.
Pageof 16

Showing results (81-90 of 152) with videos related to

Sort By:
Pageof 16
British Journal of Cancer|January 8, 2004
G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosisP Jézéquel, L Campion, M-P Joalland, et al.
Cancer|November 1, 1990
Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastasesC Jacquillat, D Khayat, P Banzet, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanomaC Jacquillat, D Khayat, P Banzet, et al.
European Journal of Cancer (Oxford, England : 1990)|December 26, 2001
Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancerF Caponigro, C Dittrich, J B Sorensen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1996
Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancerJ M Nabholtz, K Gelmon, M Bontenbal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 1, 1993
Usefulness of imaging ovarian cancer recurrence with In-111-labeled monoclonal antibody (OC 125) specific for CA 125 antigen. The INSERM Research Network (Nantes, Rennes, Reims, Vuillejuif, SaclayP Peltier, J P Dutin, J F Chatal, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2004
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group studyF Duffaud, M Borner, P Chollet, et al.
Cancer Research|June 1, 1989
Biodistribution of indium-111-labeled OC 125 monoclonal antibody intraperitoneally injected into patients operated on for ovarian carcinomasJ F Chatal, J C Saccavini, J F Gestin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2014
Trastuzumab duration effects within patient prognostic subgroups in the PHARE trialA Kramar, T Bachelot, N Madrange, et al.
Pathologie-Biologie|November 1, 1992
[Intraperitoneal recombinant gamma interferon (RU 42369) efficacy in ovarian carcinomas. European BRM Study Group]J P Guastalla, E Pujade-Lauraine, N Colombo, et al.
Pageof 16